| Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia GA Calin, CD Dumitru, M Shimizu, R Bichi, S Zupo, E Noch, H Aldler, ... Proceedings of the national academy of sciences 99 (24), 15524-15529, 2002 | 7186 | 2002 |
| miR-15 and miR-16 induce apoptosis by targeting BCL2 A Cimmino, GA Calin, M Fabbri, MV Iorio, M Ferracin, M Shimizu, ... Proceedings of the National Academy of Sciences 102 (39), 13944-13949, 2005 | 4895 | 2005 |
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National … M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 111 (12), 5446-5456, 2008 | 3939 | 2008 |
| A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia GA Calin, M Ferracin, A Cimmino, G Di Leva, M Shimizu, SE Wojcik, ... New England Journal of Medicine 353 (17), 1793-1801, 2005 | 3170 | 2005 |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2210 | 2014 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2056 | 2016 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1946 | 2014 |
| MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias GA Calin, CG Liu, C Sevignani, M Ferracin, N Felli, CD Dumitru, ... Proceedings of the National Academy of Sciences 101 (32), 11755-11760, 2004 | 1788 | 2004 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1738 | 2015 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1661 | 2018 |
| CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment JA Burger, TJ Kipps Blood 107 (5), 1761-1767, 2006 | 1488 | 2006 |
| Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia A Rosenwald, AA Alizadeh, G Widhopf, R Simon, RE Davis, X Yu, L Yang, ... The Journal of experimental medicine 194 (11), 1639-1648, 2001 | 1447 | 2001 |
| ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia LZ Rassenti, L Huynh, TL Toy, L Chen, MJ Keating, JG Gribben, ... New England Journal of Medicine 351 (9), 893-901, 2004 | 1206 | 2004 |
| Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. F Fais, F Ghiotto, S Hashimoto, B Sellars, A Valetto, SL Allen, P Schulman, ... The Journal of clinical investigation 102 (8), 1515-1525, 1998 | 1133 | 1998 |
| Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1 JA Burger, N Tsukada, M Burger, NJ Zvaifler, M Dell'Aquila, TJ Kipps Blood, The Journal of the American Society of Hematology 96 (8), 2655-2663, 2000 | 1009 | 2000 |
| MiR-15a and miR-16-1 cluster functions in human leukemia GA Calin, A Cimmino, M Fabbri, M Ferracin, SE Wojcik, M Shimizu, ... Proceedings of the National Academy of Sciences 105 (13), 5166-5171, 2008 | 995 | 2008 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 965 | 2018 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488-496, 2012 | 938 | 2012 |
| Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas GA Calin, C Liu, M Ferracin, T Hyslop, R Spizzo, C Sevignani, M Fabbri, ... Cancer cell 12 (3), 215-229, 2007 | 917 | 2007 |
| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 888 | 2019 |
